Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.51 |
| ▸ | TUBB | P07437 | 4/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625442 | 0.87 | TUBB1 (0.58) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL28275397 | 0.83 | TUBB4A (0.55) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL219096 | 0.83 | TUBB4A (0.55) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23734449 | 0.82 | TUBB1 (0.55) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL907576 | 0.82 | TPMT (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL28779745 | 0.81 | TUBB4A (0.49) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10789120 | 0.80 | TSHR (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31679677 | 0.80 | TUBB1 (0.54) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4819729 | 0.79 | TUBB4A (0.75) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL20006949 | 0.78 | TUBB1 (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794566-A1 | PIPECOLATE-DIKETOAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013091900-A1 | PIPECOLATE-DIKETOAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-06-27 | — | — | WO | disclosed |
| EP-2607352-A1 | Pipecolate-diketoamides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-06-26 | — | — | EP | disclosed |
| EP-1129070-A4 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6818643-B1 | 3,9-DIAZABICYCLO(3.3.1)NONAN-2-ONE DERIVATIVES; PEPTIDYL-PROLYL ISOMERASE (PPIASE OR ROTAMASE) INHIBITORS; NEUROPROTECTIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-16 | — | — | US | disclosed |
| US-6673809-B2 | INHIBITING RESISTANT NEOPLASM, OR NEOPLASM SUSCEPTIBLE TO RESISTANCE | ELI LILLY AND COMPANY | 2004-01-06 | — | — | US | disclosed |
| US-20030216425-A1 | Tricyclic compounds as mrp1-inhibitors | ELI LILLY AND COMPANY | 2003-11-20 | — | — | US | disclosed |
| EP-1301518-A1 | TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2001096346-A1 | TRICYCLIC COMPOUNDS AS MRP1-INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1129070-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001042245-A1 | NEUROTROPHIC BICYCLIC DIAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
| US-6228872-B1 | PEPTIDE-PROLYL ISOMERASE AND ROTAMASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-08 | — | — | US | disclosed |
| WO-2000027811-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216425-A1 | Tricyclic compounds as mrp1-inhibitors | ABCC1, ABCB1, ABCB11 | TUBB1 658/4885TUBB4A 1750/4885TUBB 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.